FL-Fc-DM1

**FL-Fc-DM1** is an investigational antibody-drug conjugate designed to target chemoresistant leukemia cells, particularly in acute myeloid leukemia (AML). It consists of a FLT3 ligand (FLT3L) fused to an Fc domain (FL-Fc fusion protein) conjugated to mertansine (DM1), a potent microtubule inhibitor and maytansinoid payload. The conjugate leverages FLT3L to specifically bind FLT3-expressing leukemic cells, facilitating targeted delivery of DM1, which disrupts microtubule dynamics, induces cell cycle arrest, and promotes apoptosis. Developed by The Seventh Affiliated Hospital of Sun Yat-sen University, it demonstrates potent anti-leukemic activity in vitro, ex vivo, and in cell line- and patient-derived xenograft models, including significant reduction in functional leukemia stem cell frequency.